Title
Increased Acid-Producing Diet and Past Smoking Intensity Are Associated with Worse Prognoses Among Breast Cancer Survivors: A Prospective Cohort Study.

Permalink
https://escholarship.org/uc/item/28b232sw

Journal
Journal of clinical medicine, 9(6)

ISSN
2077-0383

Authors
Wu, Tianying
Hsu, Fang-Chi
Pierce, John P

Publication Date
2020-06-11

DOI
10.3390/jcm9061817

Peer reviewed
Increased Acid-Producing Diet and Past Smoking Intensity Are Associated with Worse Prognoses among Breast Cancer Survivors: A Prospective Cohort Study

Tianying Wu 1,2,* , Fang-Chi Hsu 3 and John P. Pierce 2

1 Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, CA 92182, USA
2 Moores Cancer Center, School of Medicine, University of California, San Diego, CA 92093, USA; jppierce@ucsd.edu
3 Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; fhsu@wakehealth.edu

* Correspondence: tianying.wu@sdsu.edu

Received: 25 April 2020; Accepted: 5 June 2020; Published: 11 June 2020

Abstract: Current dietary guidelines do not consider cancer survivors’ and past smokers’ low capacity to regulate their acid–base balance. People with a low capacity to regulate their acid–base balance are more susceptible to acid-producing diets. We studied a cohort of 2950 early stage breast cancer survivors who provided dietary information at baseline and during follow-up. We assessed the intakes of acid-producing diets via two commonly used dietary acid load scores: potential renal acid load (PRAL) and net endogenous acid production (NEAP). We assessed past smoking intensity by pack-years of smoking. After an average of 7.3 years of follow-up, there were 295 total deaths, 249 breast cancer-specific deaths, and 490 cases of recurrent breast cancer. Increased intakes of dietary acid load and pack-years of smoking were each independently and jointly associated with increased total mortality and breast cancer-specific mortality; tests for trends and overall associations were statistically significant for NEAP and marginally significant for PRAL. Compared to women in the lowest tertile of NEAP and pack-year of smoking = 0, women in the highest tertile of NEAP and pack-years of smoking >15 had the greatest increased risk of total mortality (HR = 3.23, 95%CI 1.99–5.26). Further, dietary acid scores were associated with increased breast cancer recurrence among women with pack-years of smoking >0 but not in those with pack-years of smoking = 0 (p values for interactions <0.05). Our study provides valuable evidence for adding dietary acid load scores to dietary guidelines for breast cancer survivors and developing specific guidelines for past smokers among these survivors.

Keywords: dietary acid load; smoking status; pack-years; breast cancer survival; mortality; recurrence

1. Introduction

Cancer survivors, especially breast cancer survivors, experience accelerated aging due to the detrimental effects of cancer treatments and cancer cells as well as some additional existing risk factors among them [1–3]; thus, understanding the risk factors associated with mortality will help design efficient and specialized care for cancer survivors. Breast cancer is the most common type of cancer in women in the United States [4]. Both diet and past smoking history have been found to play important roles in breast cancer prognosis [5,6]; however, current dietary guidelines are not specifically tailored...
to breast cancer survivors or breast cancer survivors who are past smokers. Further, there is a paucity of research examining the joint impacts of diet and past smoking history on breast cancer.

Dietary acid load may play important roles in breast cancer prognosis and may interact with past smoking intensity in the development of worse prognoses in breast cancer survivors. The proper balance between the acids and bases (i.e., the pH) in the human body is crucial for normal physiologic functions and cellular metabolism [7–9]. Acid-producing diets have been found to be associated with cardiovascular-specific mortality [10,11] among healthy cancer-free populations in cohort studies. However, prospective cohort studies examining the associations of acid-producing diets with mortality among cancer survivors are limited. Cancer survivors have a reduced capacity to adjust their acid–base balance [12] and thus they may be more susceptible to acid-producing diets. Furthermore, among cancer survivors, past smokers have a lower capacity to adjust their acid–base balance than never smokers acidosis [13–15]. Past smokers accounted for up to 35–40% of breast cancer survivors, whereas current smokers only accounted for 4–6% [16–18]. Past smokers with a high intensity of past smoking history have a greater than 50% higher risk of death than never smokers among breast cancer survivors [16,19]. Thus, it is important to compare whether dietary acid load has differential adverse impacts on prognosis in past and never smokers.

We will leverage a large cohort of breast cancer survivors, the Women’s Healthy Eating and Living (WHEL) study, to conduct the current study. The range of acid-producing diets in this cohort is wider than that of the typical American diet [15], which enabled us to better evaluate the dose–response relationship. Pack-years of smoking, which can accurately assess smoking intensity, was also assessed in this cohort. This study aims to determine whether acid-producing diets and past smoking intensity are risk factors of total mortality, breast cancer-specific mortality, and breast cancer recurrence among early stage breast cancer survivors who were never smokers and past smokers at enrollment. Importantly, we will determine whether past smoking intensity can have a joint impact with an acid-producing diet or modify the impact of an acid-producing diet on breast cancer prognosis.

2. Materials and Methods

2.1. Study Design and Population

This study leverages an existing prospective cohort, the WHEL study, comprising mainly early stage (stage I, II, or IIIA) breast cancer survivors. Between 1995 and 2000, the WHEL study enrolled 3088 women within 4 years of diagnosis. The WHEL study was initially a multi-site randomized trial including several sites in the U.S. (i.e., California, Arizona, Texas, and Oregon). The trial was designed to test whether a diet low in fat and rich in vegetables, fruit, and fiber improved breast cancer prognosis. Extensive details regarding inclusion and exclusion criteria can be found in previous publications [20]. Briefly, inclusion criteria were as follows: women who had stage I (≥1 cm), II, or IIIA breast cancer diagnosed within the previous 4 years, had no evidence of cancer recurrence, had completed primary therapy, were 18–70 years old at diagnosis, did not have life-threatening comorbidities, and were able to communicate dietary data via 24-h food recall. Exclusions included insulin dependence and the diagnosis of a comorbidity requiring a specific diet or the use of a medication that contraindicated a high-fiber diet and insulin dependence. Women with diagnoses after age 70 and those with stage I tumors smaller than 1 cm were also excluded.

The initial study used several ways to identify potential participants by using tumor registries as well as communicating and distributing information to community oncologists. Participants completed a run-in period so investigators could identify who might have difficulties adhering to the study requirements. This cohort had five clinical visits in different years, while baseline, year 1, and year 4 had more complete information related to diet. The WHEL study developed an adherence score. The WHEL Feasibility Study indicated that more than 80% of participants reached an adherence score of 450 (full adherence score was 600). This initial trial provided telephone counseling and group cooking classes to the intervention group. Extensive communication programs were implemented to
build support and motivate participants to complete the program. For instance, participants could receive an airline ticket as an incentive based on the points earned. Nutritional summaries were also provided to participants after the dietary assessments [20,21].

The intervention did not significantly change breast cancer prognosis after an average of 7.3 years of follow-up. Therefore, the present study considered and analyzed the study sample as a single cohort while controlling the initial trial assignment. For this analysis, we excluded women who were current smokers at baseline; as a result, the analytical cohort comprised 2950 women.

The Institutional Review Board (IRB) at the University of California at San Diego approved the original study. All subjects provided written informed consent. The de-identified data were provided by the principal investigator of the WHEL study. The current study was an ancillary study using the de-identified data from the WHEL study; thus, the exempt IRB was approved by the San Diego State University IRB committee (protocol number: Temp-1286).

2.2. Dietary Assessment

At baseline, year 1, and year 4, dietary intakes were assessed by four prescheduled, 24-h dietary recalls collected by telephone on random days over a 3-week period: two on the weekends and two during weekdays. Dietary assessors used the multi-pass, software-driven recall protocol of the Nutritional Data System software (NDS-R, 1994–2006, 91 University of Minnesota, Minneapolis, MN, USA).

In terms of the assessment of acid-producing diets, two commonly used dietary acid load scores were used to estimate dietary acid load in epidemiological studies: the potential renal acid load (PRAL) score and the net endogenous acid production (NEAP) score. The PRAL score considers the intestinal absorption rates for contributing nutrient ionic balances for protein, potassium, calcium, and magnesium and the dissociation of phosphate at pH 7.4 [22]. Frassetto et al. [23] developed the NEAP score, which uses total protein and potassium intake as the main components involved in acid production. PRAL and NEAP scores were derived from estimations of several nutrient intakes as follows [24]:

\[
\text{PRAL (mEq/day)} = (0.49 \times \text{protein (g/day)}) + (0.037 \times \text{phosphorus (mg/day)}) - (0.021 \times \text{potassium (mg/day)}) - (0.026 \times \text{magnesium (mg/day)}) - (0.013 \times \text{calcium (mg/day)})
\]

\[
\text{NEAP (mEq/day)} = (54.5 \times \text{protein (g/day)/potassium (mEq/day)}) - 10.2
\]

This study used both scores for dietary acid assessment because they reflect slightly different nutritional intakes and biological mechanisms. A negative PRAL value reflects an alkaline-forming potential; a positive value reflects an acid-forming potential [25]. For NEAP, there is large variation in the general population (ranging from 10 to 150 mEq/day), although a typical Western diet has been characterized by a NEAP score of approximately 50 mEq/day [23,26].

2.3. Smoking Assessment

A brief smoking history questionnaire was administered to participants at baseline. The questionnaire included age of smoking initiation and cessation, duration of smoking, and the number of cigarettes/day. We classified a lifetime history of <100 cigarettes as never smoking. Former smokers reported having quit at this baseline survey. All ever smokers reported their intensity of smoking (cigarettes/day) and the number of years they smoked regularly. Pack-years exposure was determined by multiplying duration of smoking by intensity. One pack-year is equal to smoking one pack per day for one year or two packs per day for half a year for 4–6% [16].

2.4. Assessment of Study Outcome

The primary outcome of this study is total mortality, breast cancer-specific mortality, and breast cancer recurrence. At the close of the study in June 2006, vital status was known for 96% of the participants. Information on death and recurrence from participants was ascertained via confirmation interviews, periodic reviews (including with a family member), and oncologists’ reviews of the medical
record and/or death certificate. In addition, both the Social Security and the National Death Index were searched using the Social Security number, name, and date of birth. Causes of death were coded using the International Classification of Diseases, 9th Revision (ICD-9) codes. All breast cancer deaths or recurrences were confirmed by the study’s oncologist. Breast cancer recurrence was defined as the combination outcome of breast cancer recurrence (local, regional, or distal) or new primary breast cancer. Carcinoma in situ was not counted as a study outcome. Survival was assessed as the time from study entry to death or the most recent available review of the Social Security Death Index (updated until 2009). Follow-up time was censored at the earlier of (a) time of the last documented staff contact date or (b) study completion (June 2006) for participants without an event (median follow-up time was 7.3 years, range was 0.01–11.2 years). Approximately four percent of study participants were lost during follow-up and these were censored at the date of last contact.

2.5. Other Assessments

Demographic characteristics and health status, including a series of comorbid conditions (e.g., diabetes, cardiovascular diseases, digestive conditions, arthritis, osteoporosis, and medications such as diabetic, cardiovascular, and digestive medications), were self-reported.

Variables abstracted from patient records included initial cancer diagnosis and treatment. Specific variables abstracted included tumor stage, size, hormone receptor status, and use of radiation, chemotherapy, and/or post treatment anti-estrogens use. Physical activity levels were assessed using an adapted validated questionnaire from the Women’s Health Initiative [27]. Physical activity was converted into metabolic equivalent tasks (METs), as previous studies did [28].

2.6. Statistical Analyses

Differences in baseline characteristics across breast cancer prognosis or across baseline dietary acid load were evaluated using a t-test and analysis of variance (ANOVA) for normally distributed continuous variables, Wilcoxon rank-sum test and Kruskal–Wallis test for non-normally distributed continuous variables, and χ2 test for categorical variables.

We used Cox proportional hazard models to assess the association of dietary acid load with total mortality, breast cancer-specific mortality, and breast cancer recurrence. Censored times for participants who did not die were calculated from the study entry to lost to follow-up or to the end of the follow-up period, whichever came first. Event time was calculated with respect to each outcome as follows. For all-cause mortality, time was calculated from the study entry to the time of death. For breast cancer-specific mortality, time was calculated from the study entry to breast cancer-specific death; death from other causes was treated as a competing risk. For recurrent breast cancer, time was calculated from the study entry to diagnosis with recurrent breast cancer, and death was treated as a competing risk.

As previously introduced, dietary acid load was characterized by PRAL and NEAP scores. Repeated measures of PRAL and NEAP at years 0, 1, and 4 were analyzed as time-varying covariates. PRAL and NEAP scores were classified into quartiles using the average intakes at years 0, 1, and 4 to set up the cut-point for each quartile. We classified baseline pack-years of smoking into three categories (i.e., 0, 0–15, and 15+). We controlled the following covariates based on a priori assumption: age at diagnosis, race/ethnicity, education level, intervention group, menopausal status, total calorie intake, alcohol intake, smoking status, pack-years, physical activity, body mass index (BMI), education level, tumor stage, tumor size, estrogen and progesterone receptor status, type of anti-estrogen therapy, radiotherapy, chemotherapy, study site, and medical comorbidities. Among these covariates, time-varying covariates included BMI, physical activity, smoking status, total calorie intake, alcohol intake, and types of anti-estrogen therapy. We used baseline data for other covariates.

We further evaluated both joint impacts of dietary acid load and past smoking intensity on outcomes and effect modification by past smoking intensity. To evaluate joint impacts, dietary acid load was categorized by tertile to improve the stability of point estimates. Women with the lowest tertile
of dietary acid load and pack-years of smoking \(= 0\) were treated as the reference group. To evaluate the effect modification by smoking intensity, we conducted stratified analyses by two pack-years of smoking strata \((=0\) and \(>0)\). To assess whether a significant interaction occurred between dietary acid load and pack-years of smoking, we used the Wald \(p\)-value for the interaction term in a model that also included the main effects.

The proportional hazards assumption was examined and satisfied in all Cox proportional hazard regression models by testing the significance of the product terms for our variable of interest and log time. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA).

3. Results

3.1. Baseline Characteristics by Disease Outcomes in the Whole Cohort

After a median 7.3 years of follow-up, 295 deaths and 249 breast cancer-specific deaths as well as 490 breast cancer recurrences were reported in the cohort (Table 1). Compared to living group, women who died from all causes tended to have lower proportions of normal weight, above-college education, pack-years of smoking \(= 0\), and positive estrogen receptor (ER) or progesterone receptor (PR) status; they also tended to have higher proportions of women on chemotherapy and higher clinical stage (stage II and stage IIIa). The death group also tended to have lower levels of physical activities. Compared to the living group, women who died of breast cancer tended to have similar patterns to that of the all-cause mortality group except for the tamoxifen users, who tended to have a lower percentage than women who died of breast cancer. Compared to the non-recurrent group, the breast cancer recurrent group tended to have lower proportions of women who had an above-college education, were in menopause, had a positive ER or PR status, and were on tamoxifen; they also tended to have higher proportions of women on chemotherapy and higher clinical stage (stage II and stage IIIa). \(p\)-values were \(<0.05\) for these comparisons.
Table 1. Baseline characteristics of breast cancer survivors by breast cancer recurrence, total mortality and breast cancer specific mortality (n = 2950).

|                              | Total Mortality | Breast Cancer Specific Mortality | Breast Cancer Recurrence |
|------------------------------|-----------------|---------------------------------|--------------------------|
|                              | No (N = 2655)   | Yes (N = 295)                   | No (N = 2460)            | Yes (N = 490)            | p-Value |
| **PRAL (mEq/day)** a         | −3.97 (−14.11 to 4.42) | −2.93 (−13.12 to 4.51)       | −3.97 (−14.10 to 4.42)  | −2.52 (−12.59 to 5.85)  | 0.3     |
| **NEAL (mEq/day)**           | 39.78 (32.25 to 48.22) | 40.79 (33.25 to 48.89)       | 39.80 (32.21 to 48.22)  | 41.03 (33.50 to 48.68)  | 0.3     |
| **Basic**                    |                 |                                 |                          |                          |         |
| Age at diagnosis (years)     | 50.0 (45.0–57.0) | 51.0 (44.0–59.0)               | 50.0 (45.0–57.0)         | 50.0 (45.0–57.0)         | 0.3     |
| White (%)                    | 85.4 ± 0.2      |                                 | 85.4 ± 0.2               | 85.4 ± 0.3               | 0.7     |
| Body mass index              |                 |                                 |                          |                          |         |
| Normal weight (%)            | 44.0 ± 0.006    |                                 | 44.0 ± 0.006             | 43.9 ± 0.03              | 0.2     |
| Overweight or obesity (%)    | 56.0 ± 0.002    |                                 | 56.0 ± 0.002             | 56.2 ± 0.003             | 0.04    |
| Education, at or above college (%) | 56.3 ± 0.002  |                                 | 56.3 ± 0.002             | 56.3 ± 0.003             | 0.001   |
| Postmenopausal women (%)     | 79.2 ± 0.3      |                                 | 79.2 ± 0.3               | 80.2 ± 0.3               | 0.9     |
| Smoking status               |                 |                                 |                          |                          |         |
| Past smoker (%)              | 43.2 ± 0.1      |                                 | 43.2 ± 0.2               | 43.4 ± 0.2               | 0.9     |
| Never smoker (%)             | 56.8 ± 0.2      |                                 | 56.8 ± 0.2               | 56.6 ± 0.2               | 0.9     |
| Pack-year status             |                 |                                 |                          |                          |         |
| Pack-years = 0 (%)           | 56.3 ± 0.001    |                                 | 56.3 ± 0.01              | 55.7 ± 0.01              | 0.11    |
| Pack-years >10 to 15 (%)     | 27.8 ± 0.2      |                                 | 27.8 ± 0.2               | 27.7 ± 0.2               | 24.9    |
| Pack-years >15 (%)           | 14.5 ± 0.1      |                                 | 14.5 ± 0.1               | 15.1 ± 0.1               | 16.5    |
| Alcohol abstinence (%)       | 31.2 ± 0.1      |                                 | 31.2 ± 0.1               | 31.3 ± 0.1               | 0.5     |
| Physical activity (MET/week) | 600.0 ± 0.001   |                                 | 600.0 ± 0.001            | 599.0 ± 0.003            | 0.09    |
| Intervention group (%)       | 49.8 ± 0.9      |                                 | 49.8 ± 0.9               | 49.6 ± 0.7               | 0.9     |
| Chemotherapy (%)             | 68.8 ± 0.002    |                                 | 68.8 ± 0.002             | 67.9 ± 0.001             | 0.8     |
| Hormone receptor status      |                 |                                 |                          |                          |         |
| ER+/PR+ (%)                  | 62.9 ± 0.002    |                                 | 62.9 ± 0.002             | 62.9 ± 0.001             | 0.01    |
| ER-/PR- (%)                  | 21.3 ± 0.2      |                                 | 21.3 ± 0.2               | 19.1 ± 0.2               | 24.5    |
| Cancer stage at diagnosis (%)|                 |                                 |                          |                          |         |
| I                            | 40.4 ± 0.001    |                                 | 40.4 ± 0.001             | 41.9 ± 0.001             | 0.001   |
| II                           | 55.5 ± 0.001    |                                 | 55.5 ± 0.001             | 54.1 ± 0.001             | 0.001   |
| IIIa                         | 4.2 ± 0.1       |                                 | 4.2 ± 0.1                | 4.0 ± 0.1                | 10.2    |
| Tamoxifen use (%)            | 66.8 ± 0.1      |                                 | 66.8 ± 0.1               | 67.6 ± 0.009             | 0.001   |

a Continuous variables are presented as median (inter-quartile range). Abbreviations: PRAL: potential renal acid load; NEAP: net endogenous acid production; METS: metabolic equivalent/week; ER: estrogen receptor positive; PR: progesterone receptor positive.
3.2. Baseline Characteristics by Dietary Acid Load in the Whole Cohort

As shown in Table 2, compared to women with a low dietary acid load, women with a higher dietary acid load were younger and had a lower proportion of White women, postmenopausal women, positive ER or PR status women, and tamoxifen users; they included higher proportions of obese and overweight women and were likely to have less education and engage in less physical activity. \( p \)-values were < 0.01 for these comparisons.

Table 2. Baseline characteristics of breast cancer survivors by quartiles of the baseline PRAL score (\( n = 2950 \)).

| PRAL Score Quartiles (mEq/day) | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | \( p \)-Value |
|-------------------------------|------------|------------|------------|------------|--------------|
| NEAL (mEq/day) *              | 27.4 (23.9–30.7) | 36.4 (33.7–38.5) | 43.7 (41.1–46.3) | 55.4 (50.9–61.3) | <0.001 |
| Basic                         |            |            |            |            |              |
| Age at diagnosis (years)      | 52.0 (47.0–58.0) | 51.0 (46.0–58.0) | 50.0 (45.0–57.0) | 48.0 (42.0–55.0) | <0.001 |
| White (%)                     | 89.6       | 88.7       | 83.8       | 78.2       |              |
| Body mass index               |            |            |            |            |              |
| Normal weight (%)             | 56.6       | 46.7       | 37.1       | 32.8       | <0.001 |
| Overweight and obese (%)      | 43.4       | 53.3       | 63.9       | 67.2       |              |
| Education, at or above college (%) | 64.8   | 57.4       | 52.7       | 46.3       | <0.001 |
| Postmenopausal women (%)      | 84.5       | 80.1       | 80.0       | 73.2       | 0.001 |
| Smoking status                |            |            |            |            |              |
| Past smoker (%)               | 44.6       | 43.0       | 44.1       | 43.1       | 0.9 |
| Never smoker (%)              | 55.4       | 56.9       | 55.9       | 56.9       |              |
| Pack-year status              |            |            |            |            |              |
| Pack-years = 0 (%)            | 54.8       | 56.6       | 55.3       | 56.3       | 0.06 |
| Pack-years > 0 to 15 (%)      | 28.0       | 24.6       | 27.9       | 28.3       |              |
| Pack-years > 15 (%)           | 15.8       | 17.7       | 14.3       | 13.6       |              |
| Alcohol abstainer (%)         | 32.1       | 30.5       | 33.7       | 30.8       | 0.3 |
| Physical activity (MET/week)  | 825 (330–1500) | 630 (225–1335) | 480 (150–1080) | 405 (60–1080) | <0.001 |
| Chemotherapy (%)              | 63.6       | 61.4       | 59.5       | 62.5       | 0.3 |
| Radiation (%)                 | 63.6       | 61.0       | 59.1       | 62.2       | 0.6 |
| Hormone receptor status       |            |            |            |            |              |
| ER+/PR+ (%)                   | 63.2       | 63.1       | 62.3       | 58.1       | 0.003 |
| ER−/PR− (%)                   | 16.2       | 18.8       | 21.7       | 23.8       |              |
| Cancer stage at diagnosis (%) |            |            |            |            |              |
| I                             | 38.8       | 36.7       | 38.7       | 38.9       | 0.4 |
| II                            | 55.4       | 59.6       | 56.7       | 55.0       |              |
| III a                         | 5.7        | 3.7        | 4.6        | 6.2        |              |
| Tamoxifen use (%)             | 72.0       | 66.9       | 63.6       | 62.2       | 0.001 |

* Continuous variables are presented as median (inter-quartile range). Abbreviations: PRAL: potential renal acid load; NEAP: net endogenous acid production; METS: metabolic equivalent/week; ER: estrogen receptor positive; PR: progesterone receptor positive.

3.3. Dietary Acid Load, Past Smoking Intensity, and Risk of Total Mortality for Breast Cancer-Specific Mortality and Breast Cancer Recurrence

As shown in Table 3, the positive associations of dietary acid load with total mortality and breast cancer-specific mortality were statistically significant for NEAP and marginally significant for PRAL; however, no significant association was found between dietary acid load and breast cancer recurrence. The hazard ratios (HR) comparing the highest to the lowest quartiles of NEAP were 1.54 (95% confidence interval (CI) 1.04–2.29) for total mortality and 1.52 (95%CI 1.01–2.32) for breast cancer-specific mortality; \( p \)-values for trends were <0.05 for both outcomes. The corresponding HRs for PRAL were similar but marginally significant. Pack-years of smoking was positively and statistically significantly associated with the three outcomes.
### Table 3. Dietary acid load and past smoking intensity in relation to total mortality, breast cancer-specific mortality and breast cancer recurrence.

|                        | Total Mortality | Breast Cancer-Specific Mortality | Breast Cancer Recurrence |
|------------------------|-----------------|---------------------------------|--------------------------|
|                        | Event HR (95% CI) | Event HR (95% CI) | Event HR (95% CI) |
| **Dietary acid load**  |                 |                                |                          |
| PRAL (mEq/day)         |                 |                                |                          |
| Quartile 1             | Range           |                                |                          |
| &lt; -19.50            | 40              | Ref                             | 34                       | Ref                         | 61 | Ref |
| Quartile 2             | -19.50 to &lt; -6.94 | 77 | 1.17 (0.81–1.69) | 60 | 1.08 (0.73–1.54) | 133 | 0.98 (0.76–1.27) |
| Quartile 3             | -6.94 to &lt; 3.22 | 89 | 1.41 (0.97–2.06) | 80 | 1.43 (0.96–2.13) | 147 | 1.07 (0.82–1.39) |
| Quartile 4             | &gt; 3.22       | 89 | 1.30 (0.87–1.94) | 75 | 1.27 (0.83–1.94) | 149 | 1.09 (0.83–1.43) |
| **P for trend**        |                 |                                |                          |
|                       | 0.09            |                                | 0.5                      |
| NEAP (mEq/day)         | Range           |                                |                          |
| Quartile 1             | &lt; 28.44      | 35 Ref                         | 29                       | Ref                         | 61 | Ref |
| Quartile 2             | 28.44 to &lt; 37.25 | 82 | 1.27 (0.88–1.84) | 66 | 1.27 (0.87–1.87) | 127 | 1.06 (0.82–1.37) |
| Quartile 3             | 37.25 to &lt; 46.90 | 86 | 1.50 (1.02–2.21) | 77 | 1.46 (0.96–2.21) | 152 | 1.01 (0.77–1.32) |
| Quartile 4             | &gt; 46.90      | 92 | 1.54 (1.04–2.29) | 77 | 1.52 (1.01–2.32) | 150 | 1.15 (0.88–1.50) |
| **P for trend**        |                 |                                |                          |
|                       | 0.03            |                                | 0.4                      |
| **Past smoking intensity** |                 |                                |                          |
| Pack-year category     | Range           |                                |                          |
| 1                      | Range           |                                |                          |
| 0–15                   | 150             | Ref                             | 128                       | Ref                         | 273 | Ref |
| 2                      | 0.96 (0.71–1.28) | 56 | 1.02 (0.75–1.39) | 122 | 0.96 (0.77–1.17) |
| 3                      | 1.71 (1.28–2.31) | 53 | 1.68 (1.23–2.30) | 81 | 1.17 (0.91–1.51) |
| **P for trend**        |                 |                                |                          |
|                       | &lt; 0.0001     |                                | 0.001                     | 0.03                        |

HRs were derived from Cox proportional hazards regression models adjusted for multiple covariates. Covariates in the Cox model included age at diagnosis, race/ethnicity, education level, intervention group, menopausal status at baseline, total calorie intake, alcohol intake, physical activity, body mass index, number of comorbidities, tumor stage, tumor size, estrogen and progesterone receptor status, tamoxifen use, radiotherapy, and chemotherapy. Pack-years of smoking was always adjusted in the multivariable models, but PRAL and NEAP were not adjusted simultaneously. Abbreviations: HR: hazard ratio; PRAL: potential renal acid load; NEAP: net endogenous acid production; WHEL: Women’s Healthy Eating and Living study.
3.4. Joint Impact of Dietary Acid Load and Past Smoking Intensity on Breast Cancer Prognosis

We found statistically significant joint associations of dietary acid load and past smoking intensity with total mortality, breast cancer-specific mortality, and breast cancer recurrence (see Table 4). Both dietary acid load scores and smoking intensity appeared to be positively associated with total mortality. Compared to women in the lowest tertile of dietary acid load and pack-year category (pack-year of smoking = 0), women in the highest tertile of dietary acid load and pack-year category (pack-years of smoking >15) had the greatest increased risk of total mortality (HR = 2.86, 95%CI 1.73–4.74 for PRAL; HR = 3.23, 95%CI 1.99–5.26 for NEAP). p-values for trends were <0.01 for both PRAL and NEAP. We also observed that the positive associations between dietary acid load and total mortality were stronger in the highest category of pack-years of smoking (>15) than the lower two categories of pack-years of smoking (0 and 0–15). Similar patterns were observed for breast cancer-specific mortality and recurrence; however, the magnitudes and significance were attenuated for recurrence (p-values for trends were 0.1 for both PRAL and NEAP).

3.5. Stratified Associations of Dietary Acid Load with Disease Outcomes by Past Smoking Intensity

In Table 5, we observed stronger positive associations of dietary acid load with total mortality, breast cancer-specific mortality, and breast cancer recurrence in strata with pack-years of smoking >0 than strata with pack-years of smoking = 0. The positive associations tended to be stronger for NEAP (p-values for interactions were 0.1 for total mortality, 0.03 for breast cancer-specific mortality, and 0.01 for breast cancer recurrence).
Table 4. Joint associations of dietary acid load and past smoking intensity with total mortality, breast cancer-specific mortality, and breast cancer recurrence.

|                | PRAL (mEq/day) | NEAP (mEq/day) |
|----------------|----------------|----------------|
|                | Tertile 1      | Tertile 2      | Tertile 3 |
|                | N   | HR (95%CI) | N   | HR (95%CI) | N   | HR (95%CI) |
| Total mortality|     |            |     |            |     |            |
| Pack-years = 0 | 32  | Ref 60     |     | Ref 58     |     | Ref 59     |
| 0< Pack-years ≤15 | 11.3 | 1.48 (0.98–2.24) | 1.16 | 0.76–1.78) | 1.39 | 0.92–2.08 |
| Pack-years > 15 | 1.26 | 1.01 (0.58–2.10) | 1.25 | 0.63–1.74) | 1.05 | 0.65–1.86 |
| P for trend     |     | (0.71–2.21) |     | (1.73–4.74) |     | (0.76–1.81) |
| Breast cancer-specific mortality |     |            |     |            |     |            |
| Pack-years = 0 | 25  | Ref 50     |     | 1.13       | 1.13 | 0.71–1.79) |
| 0< Pack-years ≤15 | 1.17 | 0.92 (0.50–1.70) | 1.36 | 0.79–2.37) | 1.04 | 0.62–1.76 |
| Pack-years > 15 | 1.12 | 2.08 (1.19–3.63) | 2.65 | 1.54–4.57) | 1.19 | 0.66–2.14 |
| P for trend     |     | (0.61–2.06) |     | (1.54–2.14) |     | (0.66–2.14) |
| Breast cancer recurrence |     |            |     |            |     |            |
| Pack-years = 0 | 56  | Ref 106    |     | Ref 105    |     | 105         |
| 0< Pack-years ≤15 | 0.88 | 0.88 (0.61–1.28) | 0.90 | 0.67–1.21) | 0.94 | 0.54–1.17 |
| Pack-years > 15 | 18  | 0.97 (0.68–1.52) | 1.69 | 0.84 (0.53–1.34) | 1.03 | 0.66–1.59 |
| P for trend     |     | 0.50–1.25) |     | 1.10–2.64) |     | 0.66–1.46 |

HRs were derived from Cox proportional hazards regression models adjusted for multiple covariates. Covariates in the Cox model included age at diagnosis, race/ethnicity, education level, intervention group, menopausal status at baseline, total calorie intake, alcohol intake, physical activity, body mass index, number of comorbidities, tumor stage, tumor size, estrogen and progesterone receptor status, tamoxifen use, radiotherapy, and chemotherapy. PRAL and NEAP were not adjusted simultaneously. Abbreviations: HR: hazard ratio; PRAL: potential renal acid load; NEAP: net endogenous acid production; WHEL: Women’s Healthy Eating and Living study.
Table 5. Hazard ratios for total mortality, breast cancer-specific mortality and recurrence associated with dietary acid load in different pack-years of smoking strata.

| Pack-Years = 0 | Range        | Events | PRAL (mEq/day) | Breast Cancer-Specific Morality | Breast Cancer Recurrence |
|----------------|--------------|--------|----------------|---------------------------------|--------------------------|
|                |              |        | HR (95%CI)     | HR (95%CI)                      | Events                   |
| Quartile 1     | <−19.50      | 21     | Ref            | Ref                             | 38                       |
| Quartile 2     | −19.50 to <−6.94 | 41     | 1.07 (0.64–1.79) | 1.04 (0.58–1.85)               | 75                       |
| Quartile 3     | −6.94 to <−3.22 | 45     | 1.35 (0.80–2.29) | 1.31 (0.71–2.43)               | 73                       |
| Quartile 4     | ≥3.22        | 43     | 1.10 (0.63–1.93) | 1.13 (0.60–2.10)               | 87                       |
| P for trend    |              |        | 0.6            | 0.6                             | 0.9                      |
| Pack-Years > 0 | Range        | Events | NEAP (mEq/day) | HR (95%CI)                      | Events                   |
|                |              |        | HR (95%CI)     | HR (95%CI)                      | Events                   |
| Quartile 1     | <−19.50      | 17     | Ref            | Ref                             | 21                       |
| Quartile 2     | −19.50 to <−6.94 | 33     | 1.17 (0.69–1.99) | 1.03 (0.56–1.90)               | 53                       |
| Quartile 3     | −6.94 to <−3.22 | 41     | 1.45 (0.84–2.49) | 1.54 (0.86–2.75)               | 71                       |
| Quartile 4     | ≥3.22        | 42     | 1.51 (0.84–2.69) | 1.54 (0.79–3.01)               | 58                       |
| P for trend    |              |        | 0.1            | 0.6                             | 0.1                      |
| P for interaction |          |        | 0.4            | 0.9                             | 0.03                     |

| Pack-Years = 0 | Range        | Events | HR (95%CI)     | HR (95%CI)                      | Events                   |
|----------------|--------------|--------|----------------|---------------------------------|--------------------------|
|                |              |        | PRAL (mEq/day) | Breast Cancer-Specific Morality | Breast Cancer Recurrence |
| Quartile 1     | <−28.44      | 17     | Ref            | Ref                             | 32                       |
| Quartile 2     | 28.44 to <−37.25 | 48     | 1.26 (0.76–2.10) | 1.26 (0.72–2.23)               | 78                       |
| Quartile 3     | 37.25 to <−46.90 | 40     | 1.46 (0.86–2.50) | 1.39 (0.74–2.61)               | 79                       |
| Quartile 4     | ≥46.90       | 45     | 1.30 (0.75–2.27) | 1.29 (0.70–2.39)               | 84                       |
| P for trend    |              |        | 0.4            | 0.6                             | 0.9                      |
| Pack-Years > 0 | Range        | Events | NEAP (mEq/day) | HR (95%CI)                      | Events                   |
|                |              |        | HR (95%CI)     | HR (95%CI)                      | Events                   |
| Quartile 1     | <−28.44      | 16     | Ref            | Ref                             | 25                       |
| Quartile 2     | 28.44 to <−37.25 | 32     | 1.25 (0.74–2.15) | 1.20 (0.67–2.13)               | 47                       |
| Quartile 3     | 37.25 to <−46.90 | 41     | 1.44 (0.82–2.53) | 1.38 (0.75–2.56)               | 68                       |
| Quartile 4     | ≥46.90       | 44     | 1.81 (1.04–3.16) | 1.88 (0.75–2.55)               | 63                       |
| P for trend    |              |        | 0.03           | 0.04                            | 0.09                     |
| P for interaction |          |        | 0.1            | 0.03                            | 0.01                     |

HRs were derived from Cox proportional hazards regression models adjusted for multiple covariates. Covariates in the Cox model included age at diagnosis, race/ethnicity, education level, intervention group, menopausal status at baseline, total calorie intake, alcohol intake, physical activity, body mass index, number of comorbidities, tumor stage, tumor size, estrogen and progesterone receptor status, tamoxifen use, radiotherapy, and chemotherapy. PRAL and NEAL were not adjusted simultaneously. Abbreviations: HR: hazard ratio; PRAL: potential renal acid load; NEAL: net endogenous acid production; WHEL: Women’s Healthy Eating and Living study.
4. Discussion

In these comprehensive analyses of a cohort of breast cancer survivors, increased dietary acid load and past smoking intensity were both independently and jointly associated with increased total mortality and breast cancer-specific mortality. We also found an increased risk of breast cancer recurrence among women with pack-years of smoking >0.

Our study is the first to highlight the importance of the independent and joint impacts of dietary acid load and past smoking intensity on total mortality, breast-cancer specific mortality and recurrence among early stage breast cancer survivors. Previous prospective studies have demonstrated that the dietary acid load or higher metabolic acid load (measured by lower serum bicarbonate and overnight fasting urine pH) had a positive or U-shaped relationship with total mortality or cardiovascular mortality but not with cancer-associated mortality [10,29,30]. These studies followed apparently healthy individuals without cancer at baseline [10,29,30]; thus, whether dietary acid load is associated with total and cancer-specific mortality among cancer survivors cannot be concluded from these studies. Dietary acid load has been shown to increase the risk of hypertension, diabetes, chronic kidney diseases, and hip fractures in cohort studies [31–35]; all of these are risk factors for total mortality [36–38]. Furthermore, animal studies have shown that metabolic acidosis can lead to increased cancer development and metastasis [39]. The following discussion helps explain some of the mechanisms. Cancer or cancer treatment itself can damage our bodily systems (electrolytes, respiratory system, kidneys or bone) that need to adjust the acid–base balance [12]. Further, among cancer patients, adaptation to acidosis, in conjunction with oncogenic mutations, endows cancer cells with increased fitness for survival [40]. An acidic microenvironment suppresses antitumor immune responses [41,42] and facilitates treatment resistance [43].

We propose the following to help explain why NEAP was found to be a better predictor of breast cancer prognosis than PRAL in our study. Both PRAL and NEAP have their own advantages and disadvantages. NEAP is an approximate of renal net acid excretion (RNAE) and was found to account for 70% of the variation of RNAE [23]. It is a simple estimate of RNAE when compared to PRAL, which considers the roles of other minerals from diets in regulating acid–base balance. PRAL does rely on more information from the dietary database, reduce the predictabilities if the roles of other minerals are negligible, or potentially add measurement errors if the information from other minerals are not accurate or the absorption rates of other minerals varied largely across individuals [26,44]. For instance, Frasseto found that, when adding magnesium to the NEAP score to predict RNAE in 141 healthy subjects (aged 17–73), it actually increased the unaccounted variability by 10% [23]. Moreover, although NEAP and PRAL have strong correlations (r = 0.9), PRAL does not estimate RNAE well when the protein intakes are in low or high ranges [26,44]. It is possible that PRAL has better predictive values than NEAP when minerals other than potassium play important roles in disease development. For instance, PRAL is more predictive of cardiovascular mortality among patients who underwent coronary artery bypass grafting surgery [11] and of depression [45,46]. Other minerals, such as magnesium and calcium, do play important roles in heart functions [47,48] and in the development of depression [49–51]. Nevertheless, our study indicates that NEAP, which includes only two key elements (protein and potassium), is an important predictor for total mortality and breast cancer-specific mortality in the whole cohort, and for breast cancer recurrence among past smokers. It also suggests that renal function could be one of the key determining factors in these relationships. Future studies should estimate renal functions to unravel the biological mechanism.

Several mechanisms can explain why past smokers are more susceptible to dietary acid load than never smokers. Quitting smoking can avoid further damage but does not remove past damages by smoking [16,52]; smoking can further damage the acid–base regulating systems [53–56] and can promote acidosis in patients with or without cancer [13,14]. All of these factors help explain the mechanisms associated with the accelerated risk of total mortality, breast cancer-specific mortality and recurrence for past smokers among breast cancer survivors.
The original intervention was a low-fat, high-fruit, and -vegetable dietary intervention, not an intervention aiming to change dietary acid load scores, though we did find that dietary acid load scores were significantly lower in the intervention group than the control group. One may question why dietary acid load was found to have a significant impact on prognosis whereas the original intervention did not have a significant impact on prognosis. There are several possible reasons for this. Dietary acid load scores were greatly reduced in the intervention group when compared to the control group; however, 17% and 53% from the intervention group still had high NEAP scores (higher than median) at year 1 and 4, respectively, as compared to 54% and 63% from the control group. Such a mismatch can significantly attenuate the association if it were analyzed as a clinical trial. In addition to dietary acid load, types of fat and intakes of refined carbohydrates were not controlled in the original WHEL intervention. As we know, diets with high intakes of trans fatty acids and glycemic load can increase inflammation and hyperglycemia [57,58], which are risk factors for mortality and cancer recurrence [36,59–62].

This study has several strengths. It is the first large prospective cohort study investigating the independent and joint associations of dietary acid load and past smoking intensity with breast cancer prognosis among breast cancer survivors. Four 24-h recalls during each visit (baseline, year 1, and year 4) were the unique advantages of this cohort but were rarely conducted in other cohorts. Such advantages enable us to assess dietary acid load more accurately and examine its longitudinal relationships with prognosis outcomes. As this study was originally a trial of high-vegetable, high-fruit, and low-fat intake interventions, we observed a wider range of dietary acid load than other cohorts. This study assessed pack-years of smoking, which can better evaluate past smoking intensity than smoking status. The large sample size provided us with sufficient power to adjust for multiple covariates. However, this study also has limitations. This cohort’s follow-up time was relatively short, and this cohort was comprised predominantly of White women, which will not allow us to examine long-term impacts or generalize our results to other ethnic groups. There was also the possibility of volunteer bias, as the women in the WHEL cohort were highly motivated, health-conscious breast cancer survivors. HER2 status was not available for the WHEL participants, which may have resulted in residual confounding. WHEL participants were enrolled up to 4 years after their initial diagnosis; thus, the study may not represent breast cancer patients who recur shortly after diagnosis.

5. Conclusions

Current dietary guidelines, such as the American Cancer Society’s (ACS) dietary guidelines for breast cancer survivors, do not include dietary acid load and specific dietary guidelines for former smokers [63,64]. Increased dietary acid load and past smoking intensity are both independently and jointly associated with increased total mortality, breast cancer-specific mortality, and recurrence. Monitoring and reducing the protein-to-potassium ratio is important for preventing adverse prognoses among breast cancer survivors. Our results provide important messages for clinicians and dietitians. Precision care and individualized nutrition for breast cancer survivors are important emerging trends. Our results provide valuable evidence for modifying current ACS dietary guidelines regarding dietary acid load and offer specific guidelines for past smokers with different past smoking intensities.

Author Contributions: T.W. designed and developed the research plan and conducted the main analyses. F.-C.H. and T.W. help create the statistical program. T.W. wrote the manuscript. F.-C.H. provided comments and edits for the manuscript. J.P.P. was the P.I. of the WHEL study and collected the dietary, covariate and outcome data. T.W. had primary responsibility for the final content. All authors have read and agreed to the published version of the manuscript.

Funding: This research is partially supported by California Tobacco-Related Research Program (TRDRP)—T30IP0998 and San Diego State University state funds. The WHEL study was initiated with the support of the Walton Family Foundation and continued with funding from National Cancer Institute grant CA 69375.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Henderson, T.O.; Ness, K.K.; Cohen, H.J. Accelerated aging among cancer survivors: From pediatrics to geriatrics. Am. Soc. Clin. Oncol. Educ. Book 2014, 34, e423–e430. [CrossRef] [PubMed]

2. Chang, L.; Weiner, L.S.; Hartman, S.J.; Horvath, S.; Jeste, D.; Mischel, P.S.; Kado, D.M. Breast cancer treatment and its effects on aging. J. Geriatr. Oncol. 2019, 10, 346–355. [CrossRef] [PubMed]

3. Cupit-Link, M.C.; Kirkland, J.L.; Ness, K.K.; Armstrong, G.T.; Tchkonia, T.; LeBrasseur, N.K.; Armenian, S.H.; Ruddy, K.J.; Hashmi, S.K. Biology of premature ageing in survivors of cancer. ESMO Open 2017, 2, e000250. [CrossRef] [PubMed]

4. Cancer Facts and Figures. American Cancer Society. 2019.

5. Rico-Campa, A.; Martinez-González, M.; Alvarez-Alvarez, I.; Mendonça, R.D.D.; De La Fuente-Arrillaga, C.; Gómez-Donoso, C.; Bes-Rastrollo, M. Association between consumption of ultra-processed foods and all cause mortality: SUN prospective cohort study. BMJ 2019, 365, l1949. [CrossRef] [PubMed]

6. Veronese, N.; Cisternino, A.M.; Shivappa, N.; Hebert, J.R.; Notarnicola, M.; Reddavide, R.; Ingugliato, R.; Guerra, V.; Logroscino, A.; Rotolo, O.; et al. Dietary inflammatory index and mortality: A cohort longitudinal study in a Mediterranean area. J. Hum. Nutr. Diet. 2020, 33, 138–146. [CrossRef]

7. Hamm, L.L.; Nakhoul, N.; Hering-Smith, K.S. Acid-Base Homeostasis. In Onco-Nephrology Curriculum; American Society of Nephrology: San Diego, CA, USA, 2016.

8. Alguacil, J.; Kogevinas, M.; Silverman, D.T.; Malats, N.; Real, F.X.; García-Closas, M.; Tardón, A.; Rivas, M.; Torá, M.; García-Closas, R.; et al. Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis 2011, 32, 843–847. [CrossRef] [PubMed]

9. Wu, T.; Seaver, P.; Lemus, H.; Hollenbach, K.; Wang, S.E.; Pierce, J. Associations between Dietary Acid Load and Biomarkers of Inflammation and Hyperglycemia in Breast Cancer Survivors. Nutrients 2019, 11, 1913. [CrossRef] [PubMed]

10. Saquib, N.; Stefanick, M.L.; Natarajan, L.; Pierce, J. Mortality risk in former smokers with breast cancer: Pack-years vs. smoking status. Int. J. Cancer 2013, 133, 2493–2497. [CrossRef] [PubMed]

11. Munger, K.L.; Levin, L.I.; Massa, J.; Horst, R.; Orban, T.; Ascherio, A. Preclinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am. J. Epidemiol. 2013, 177, 411–419. [CrossRef] [PubMed]

12. Lafourcade, A.; His, M.; Baglietto, L.; Boutron-Ruault, M.-C.; Dossus, L.; Rondeau, V. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: The French E3N cohort. BMC Cancer 2018, 18, 171. [CrossRef]

13. Duan, W.; Li, S.; Meng, X.; Sun, Y.; Jia, C. Smoking and survival of breast cancer patients: A meta-analysis of cohort studies. Breast 2017, 33, 117–124. [CrossRef]

14. Pierce, J.P.; Faerber, S.; A Wright, F.; Rock, C.L.; Newman, V.; Flatt, S.W.; Kealey, S.; E Jones, V.; Caan, B.J.; Gold, E.B.; et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: The Women’s Healthy Eating and Living (WHEL) Study. Control Clin. Trials 2002, 23, 728–756. [CrossRef]
21. Pierce, J.P.; Natarajan, L.; Caan, B.J.; Parker, B.A.; Greenberg, E.R.; Flatt, S.W.; Rock, C.L.; Kealey, S.; Al-Delaimy, W.K.; Bardwell, W.A.; et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: The Women's Healthy Eating and Living (WHEL) randomized trial. *JAMA* 2007, 298, 289–298. [CrossRef]

22. Remer, T.; Manz, F. Potential renal acid load of foods and its influence on urine pH. *J. Am. Diet Assoc.* 1995, 95, 791–797. [CrossRef]

23. Frassetto, L.A.; Todd, K.M.; Morris, R.C.; Sebastian, A. Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. *Am. J. Clin. Nutr.* 1998, 68, 576–583. [CrossRef] [PubMed]

24. Remer, T.; Dimitriou, T.; Manz, F. Dietary potential renal acid load and renal net acid excretion in healthy, free-living children and adolescents. *Am. J. Clin. Nutr.* 2003, 77, 1255–1260. [CrossRef]

25. Engberink, M.F.; Bakker, S.J.; Brink, E.J.; Van Baak, M.; Van Rooij, F.J.; Hofman, A.; Witteman, J.C.; Geleijnse, J.M. Dietary acid load and risk of hypertension: The Rotterdam Study. *Am. J. Clin. Nutr.* 2012, 95, 1438–1444. [CrossRef] [PubMed]

26. Frassetto, L.A.; Morris, R.C., Jr.; Sebastian, A. A practical approach to the balance between acid production and renal acid excretion in humans. *J. Nephrol.* 2006, 19 (Suppl. 9), S33–S40. [PubMed]

27. Johnson-Kozlow, M.; Rock, C.L.; Gilpin, E.A.; Hollenbach, K.A.; Pierce, J. Validation of the WHI brief physical activity questionnaire among women diagnosed with breast cancer. *Am. J. Health Behav.* 2007, 31, 193–202. [CrossRef] [PubMed]

28. Hong, S.; Bardwell, W.A.; Natarajan, L.; Flatt, S.W.; Rock, C.L.; Newman, V.A.; Madlensky, L.; Mills, P.J.; Dimsdale, J.E.; Thomson, C.A.; et al. Correlates of physical activity level in breast cancer survivors participating in the Women’s Healthy Eating and Living (WHEL) Study. *Breast Cancer Res. Treat* 2007, 101, 225–232. [CrossRef]

29. Xu, H.; Åkesson, A.; Orsini, N.; Håkansson, N.; Wolk, A.; Carrero, J.-J. Modest U-Shaped Association between Dietary Acid Load and Risk of All-Cause and Cardiovascular Mortality in Adults. *J. Nutr.* 2016, 146, 1580–1585. [CrossRef]

30. Park, M.; Jung, S.J.; Yoon, S.; Yun, J.M.; Yoon, H.-J. Association between the markers of metabolic acid load and higher all-cause and cardiovascular mortality in a general population with preserved renal function. *Hypertens Res.* 2015, 38, 433–438. [CrossRef]

31. Fagherazzi, G.; Vilier, A.; Bonnet, E.; Lajous, M.; Balkau, B.; Boutron-Ruault, M.-C.; Clavel-Chapelon, F. Dietary acid load and risk of type 2 diabetes: The E3N-EPIC cohort study. *Diabetologia* 2014, 57, 313–320. [CrossRef]

32. Zhang, L.; Curhan, G.C.; Forman, J.P. Diet-dependent net acid load and risk of incident hypertension in United States women. *Hypertension* 2009, 54, 751–755. [CrossRef]

33. Rebholz, C.M.; Coresh, J.; Grams, M.E.; Steffen, L.M.; Anderson, C.A.; Appel, L.J.; Crews, D.C. Dietary Acid Load and Incident Chronic Kidney Disease: Results from the ARIC Study. *Am. J. Nephrol.* 2015, 42, 427–435. [CrossRef] [PubMed]

34. Sellmeyer, D.E.; Stone, K.L.; Sebastian, A.; Cummings, S.R. A high ratio of dietary animal to vegetable protein increases the rate of bone loss and the risk of fracture in postmenopausal women. Study of Osteoporotic Fractures Research Group. *Am. J. Clin. Nutr.* 2001, 73, 118–122.

35. Gaede, J.; Nielsen, T.; Madsen, M.L.; Toft, U.; Jorgensen, T.; Overvad, K.; Tjonneland, A.; Hansen, T.; Allin, K.H. Pedersen, O. Population-based studies of relationships between dietary acidity load, insulin resistance and incident diabetes in Danes. *Nutr. J.* 2018, 17, 91. [CrossRef] [PubMed]

36. Rawshani, A.; Franzén, S.; Sattar, N.; Eliasson, B.; Svensson, A.-M.; Zethelius, B.; Miftaraj, M.; McGuire, D.K.; Rosengren, A.; Gudbjörnsdottir, S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N. Engl. J. Med.* 2018, 379, 633–644. [CrossRef] [PubMed]

37. Morri, M.; Ambrosi, E.; Chiari, P.; Magli, A.O.; Gazimeo, D.; Alessandro, F.D.; Forni, C. One-year mortality after hip fracture surgery and prognostic factors: A prospective cohort study. *Sci. Rep.* 2019, 9, 18718. [CrossRef] [PubMed]

38. Wen, C.P.; Cheng, T.Y.D.; Tsai, M.-K.; Chang, Y.C.; Chan, H.-T.; Tsai, S.P.; Chiang, P.H.; Hsu, C.-C.; Sung, P.K.; Hsu, Y.H.; et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. *Lancet* 2008, 371, 2173–2182. [CrossRef]
39. Kato, Y.; Ozawa, S.; Miyamoto, C.; Maehata, Y.; Suzuki, A.; Maeda, T.; Baba, Y. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013, 13, 89. [CrossRef]
40. Boedtkjer, E.; Pedersen, S.F. The Acidic Tumor Microenvironment as a Driver of Cancer. Annu. Rev. Physiol. 2020, 82, 103–126.
41. Calcino, A.; Filipazzi, P.; Grioni, M.; Iero, M.; De Milioto, A.; Ricupito, A.; Cova, A.; Canese, R.; Jachetti, E.; Rossetti, M.; et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012, 72, 2746–2756. [CrossRef]
42. Huber, V.; Camisaschi, C.; Berzi, A.; Ferro, S.; Lugini, L.; Triulzi, T.; Tuccito, A.; Tagliabue, E.; Castelli, C.; Rivoltini, L. Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin. Cancer Biol. 2017, 43, 74–89. [CrossRef]
43. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441–1454. [CrossRef] [PubMed]
44. Remer, T.; Manz, F. Estimation of the renal net acid excretion by adults consuming diets containing variable amounts of protein. Am. J. Clin. Nutr. 1994, 59, 1356–1361. [CrossRef]
45. Daneshzad, E.; Keshavarz, S.-A.; Qorbani, M.; Larijani, B.; Bellissimo, N.; Azadbakht, L. Association of dietary acid load and plant-based diet index with sleep, stress and depression in diabetic women. Br. J. Nutr. 2020, 123, 901–912. [CrossRef] [PubMed]
46. Buhlmeier, J.; Harris, C.; Koletzko, S.; Lehmann, I.; Bauer, C.-P.; Schikowski, T.; Von Berg, A.; Berdel, D.; Heinrich, J.; Hebebrand, J.; et al. Dietary Acid Load and Mental Health Outcomes in Children and Adolescents: Results from the GINInplus and LISA Birth Cohort Studies. Nutrients 2018, 10, 582. [CrossRef] [PubMed]
47. Marks, A.R. Calcium and the heart: A question of life and death. J. Clin. Investig. 2003, 111, 597–600. [CrossRef] [PubMed]
48. Taveira, T.H.; Ouellette, D.; Gulüm, A.; Choudhary, G.; Eaton, C.B.; Liu, S.; Wu, W.-C. Relation of Magnesium to Cardiac Function and Failure Hospitalizations in Black Adults: The Jackson Heart Study. Circ. Heart Fail. 2016, 9, e002698. [CrossRef]
49. Yary, T.; Lehto, S.M.; Tolmunen, T.; Tuomainen, T.-P.; Kauhanen, J.; Voutilainen, S.; Ruusunen, A. Dietary magnesium intake and the incidence of depression: A 20-year follow-up study. J. Affect. Disord. 2016, 193, 94–98. [CrossRef]
50. Tarleton, E.K.; Littenberg, B. Magnesium intake and depression in adults. J. Am. Board Fam. Med. 2015, 28, 249–256. [CrossRef]
51. Frizel, D.; Coppen, A.; Marks, V. Plasma magnesium and calcium in depression. Br. J. Psychiatry 1969, 115, 1375–1377. [CrossRef]
52. Pierce, J.P.; Patterson, R.E.; Senger, C.M.; Flatt, S.W.; Caan, B.J.; Natarajan, L.; Nechuta, S.J.; Poole, E.M.; Shu, X-O.; Chen, W.Y. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Screening Trial. J. Natl. Cancer Inst. 2007, 99, 582. [CrossRef] [PubMed]
53. Okada, Y.; Tsuzuki, Y.; Ueda, T.; Hozumi, H.; Sato, S.; Hokari, R.; Kurihara, C.; Watanabe, C.; Tomita, K.; Komoto, S.; et al. Trans fatty acids in diets act as a precipitating factor for gut inflammation? J. Gastroenterol. Hepatol. 2013, 28 (Suppl. 4), 29–32. [CrossRef] [PubMed]
54. Yacoub, R.; Habib, H.; Lahdo, A.; Al Ali, R.; Varjabedian, L.; Atalla, G.; Akl, N.K.; Aldakheel, S.; Alahdab, S.; Albitar, S. Association between smoking and chronic kidney disease: A case control study. BMC Public Health 2010, 10, 731. [CrossRef]
55. Tantisuwat, A.; Thaveeratitham, P. Effects of smoking on chest expansion, lung function, and respiratory muscle strength of youths. J. Phys. Ther. Sci. 2014, 26, 167–170. [CrossRef]
56. Law, M.R.; Hackshaw, A.K. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: Recognition of a major effect. BMJ 1997, 315, 841–846. [CrossRef]
57. Okada, Y.; Tsuzuki, Y.; Ueda, T.; Hozumi, H.; Sato, S.; Rurihara, C.; Watanabe, C.; Tomita, K.; Komoto, S.; et al. Trans fatty acids in diets act as a precipitating factor for gut inflammation? J. Gastroenterol. Hepatol. 2013, 28 (Suppl. 4), 29–32. [CrossRef] [PubMed]
58. Fabricatore, A.N.; Ebbeling, C.B.; A Wadden, T.; Ludwig, D.S. Continuous glucose monitoring to assess the ecologic validity of dietary glycemic index and glycemic load. Am. J. Clin. Nutr. 2011, 94, 1519–1524. [CrossRef] [PubMed]
59. Erickson, K.; Patterson, R.E.; Flatt, S.W.; Natarajan, L.; Parker, B.A.; Heath, D.D.; Laughlin, G.A.; Saquib, N.; Rock, C.L.; Pierce, J. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. *J. Clin. Oncol.* 2011, 29, 54–60. [CrossRef] [PubMed]

60. Fujiwara, Y.; Haruki, K.; Shiba, H.; Hamura, R.; Horiuchi, T.; Shirai, Y.; Furukawa, K.; Gocho, T.; Yanaga, K. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curative Resection for Pancreatic Cancer. *Anticancer Res.* 2018, 38, 6491–6499. [CrossRef]

61. Bonaccio, M.; Di Castelnuovo, A.; Pounis, G.; De Curtis, A.; Costanzo, S.; Persichillo, M.; Cerletti, C.; Donati, M.; De Gaetano, G.; Iacoviello, L. A score of low-grade inflammation and risk of mortality: Prospective findings from the Moli-sani study. *Haematologica* 2016, 101, 1434–1441. [CrossRef]

62. Proctor, M.J.; McMillan, D.C.; Horgan, P.G.; Fletcher, C.D.; Talwar, D.; Morrison, D.S. Systemic inflammation predicts all-cause mortality: A glasgow inflammation outcome study. *PLoS ONE* 2015, 10, e0116206. [CrossRef]

63. Rock, C.L.; Doyle, C.; Demark-Wahnefried, W.; Meyerhardt, J.; Courneya, K.S.; Schwartz, A.L.; Bandera, E.V.; Hamilton, K.K.; Grant, B.; McCullough, M.; et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J. Clin.* 2012, 62, 243–274. [CrossRef] [PubMed]

64. Runowicz, C.D.; Leach, C.R.; Henry, N.L.; Henry, K.S.; Mackey, H.T.; Cowens-Alvarado, R.L.; Cannady, R.S.; Pratt-Chapman, M.L.; Edge, S.B.; Jacobs, L.A.; et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *J. Clin. Oncol.* 2016, 34, 611–635. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).